Golimumab

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断

Golimumab (CNTO-148) 是一种有效的人 IgG1 TNFα 拮抗剂单克隆抗体。Golimumab 具有抗炎活性，并抑制 IL-6 和 IL-1β 的产生。Golimumab 通过靶向和中和 TNF 来防止炎症发生和软骨或骨骼的破坏。Golimumab 具有抗癌活性并诱导细胞凋亡 (apoptosis)。Golimumab 可用于类风湿关节炎、克罗恩病和癌症研究。

Golimumab (CNTO-148) is a potent human IgG1 TNFα antagonist monoclonal antibody. Golimumab has anti-inflammation activitity and inhibits IL-6 and IL-1β production. Golimumab acts via targeting and neutralizing TNF to prevent inflammation and destruction of cartilage and bone. Golimumab has the anticancer activity and induces cell apoptosis. Golimumab can be used for rheumatoid arthritis, Crohn's disease and cancer research.

Golimumab (CNTO-148) (0.1-10 μg /mL; 24-72 hours; transmembrane TNFα–transfected Jurkat cells) induces reductions in the viability of transmembrane TNFα–expressing cells.Golimumab (CNTO-148) (10 μg /mL; 48 hours; transmembrane TNFα–transfected Jurkat cells) induces apoptosis, increase the levels of active caspase-3 and induces apoptotic DNA fragmentation.Cell Viability Assay Cell Line:Transmembrane TNFα–transfected Jurkat cells Concentration:0.1, 1 and 10 μg/mL Incubation Time:24, 48 and 72 hours Result:Reduced cell viability in a dose- and time-dependent manner.Apoptosis Analysis Cell Line:Transmembrane TNFα–transfected Jurkat cells Concentration:10 μg /mL Incubation Time:48 hours Result:Had the percentage of apoptotic cells for 30.29%.Western Blot Analysis Cell Line:Transmembrane TNFα–transfected Jurkat cellsConcentration:10 μg /mL Incubation Time:48 hours Result:Increased the levels of active caspase-3 and induces apoptotic DNA fragmentation.

Golimumab (CNTO-148) (24 mg/kg; i.h.; daily, for 7 days; swiss-albino healthy male mice) inhibits oxidative stress, apoptotic cell death inflammatory response, thus improving renal function. Golimumab reduces all markers of kidney injury and attenuates cell death.Golimumab (CNTO-148) (1-10 mg/kg; i.p.;daily; for 4 weeks; Tg197 transgenic mouse model) relieves TNFα-induced arthritis in a mouse model of human.Animal Model:Swiss-albino healthy male mice Dosage:24 mg/kg Administration: Subcutaneous injection; daily, for 7 days Result:Reduced serum parameters like BUN, NGAL creatinine, cystatin C, and urinary parameters like KIM-1, NAG, albumin clusterin.Animal Model:Swiss-albino healthy male miceDosage:24 mg/kg Administration:Subcutaneous injection; daily, for 7 days Result:Inhibited oxidative stress, reduces MDA concentrations and increases the GSH and catalase levels.Animal Model:Swiss-albino healthy male mice Dosage:24 mg/kg Administration: Subcutaneous injection; daily, for 7 days Result:Inhibitd cisplatin-induced inflammation, decreased TNF-α, including IL-6, IL-1β, MCP-1, ICAM-1, and TGF-β1 levels and increases IL-10 concentrations, reduced caspase 3 in cisplatin injected mice kidneys.Animal Model:Tg197 transgenic mouse model Dosage:1 and 10 mg/kg Administration:Intraperitoneal injection;for 4 weeks Result:Reduced the arthritic index.

——

Apoptosis

TNF

TNF

——

——

476181-74-5

146.93KD

——

>98% (HPLC)

——

——

——

(-20℃)

With Ice Pack

≥ 2 years